- Rethymic — Enzyvant Therapeutics’ drug is designed to treat children with congenital athymia, a rare immune disorder in which a child is born without a thymus, an organ that plays a critical role in helping the body learn to fight infections.
- Byooviz — The first biosimilar biosimilar drug to Roche’s Lucentis treats several eye diseases. Byooviz is made by Samsung Bioepis.
- Vivistim Paired VNS System — A device, made by MicroTransponder, is intended to treat moderate to severe upper extremity motor deficits caused by a stroke.
- Comirnaty — Pfizer’s COVID-19 vaccine, the first to receive full approval from the FDA. Moderna and Johnson & Johnson’s COVID-19 vaccines haven’t received full approval and are available under emergency use authorizations.
- Xywav — Jazz Pharmaceuticals’ drug is used to treat a rare sleep condition.
- Nexviazyme — Genzyme’s drug is used to treat Pompe disease, a rare genetic disease that causes muscle weakness and premature death from respiratory or heart failure.
- Semglee — Made by Mylan, it’s the first interchangeable biosimilar insulin product approved in the U.S.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
